Glucantime-resistant Leishmania tropica isolated from Iranian patients with cutaneous leishmaniasis are sensitive to alternative antileishmania drugs

Parasitology Research

Volumn 101, Issue 5, 2007, Pages 1319-1322

  Hadighi, R ^a   Boucher, P ^b   Khamesipour, A ^c   Meamar, A R ^a   Roy, G ^b   Ouellette, M ^b   Mohebali, M ^d  

^a IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b LAVAL UNIVERSITY   (Canada)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; MEGLUMINE ANTIMONATE; MILTEFOSINE; PAROMOMYCIN; STIBOGLUCONATE SODIUM;

ARTICLE; CONTROLLED STUDY; CROSS RESISTANCE; DRUG RESISTANCE; HUMAN; HUMAN CELL; IRAN; LEISHMANIA TROPICA; NONHUMAN; PARASITE ISOLATION; PRIORITY JOURNAL; SKIN LEISHMANIASIS; VISCERAL LEISHMANIASIS;

AMPHOTERICIN B; ANIMALS; ANTIMONY SODIUM GLUCONATE; ANTIPROTOZOAL AGENTS; DRUG RESISTANCE; HUMANS; IRAN; LEISHMANIA TROPICA; LEISHMANIASIS, CUTANEOUS; MEGLUMINE; ORGANOMETALLIC COMPOUNDS; PARASITIC SENSITIVITY TESTS; PAROMOMYCIN; PHOSPHORYLCHOLINE;

LEISHMANIA TROPICA;

EID: 34548555598     PISSN: 09320113     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00436-007-0638-0     Document Type: Article

References (27)

1. Arana FE, Perez-Victoria JM, Repetto Y, Morello A, Castanys S, Gamarro F (1998) Involvement of thiol metabolism in resistance to glucantime in Leishmania tropica (in process citation). Biochem Pharmacol 56:1201-1208
2. Carrio J, Riera C, Gallego M, Ribera E, Portus M (2001) In vitro susceptibility of Leishmania infantum to meglumine antimoniate in isolates from repeated leishmaniasis episodes in HIV-coinfected patients. J Antimicrob Chemother 47:120-121
3. Croft SL, Sundar S, Fairlamb AH (2006) Drug resistance in leishmaniasis. Clin Microbiol Rev 19:111-126
4. Das VN, Ranjan A, Bimal S, Siddique NA, Pandey K, Kumar N, Verma N, Singh VP, Sinha PK, Bhattacharya SK (2005) Magnitude of unresponsiveness to sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar. Natl Med J India 18:131-133
5. Decuypere S, Rijal S, Yardley V, De Doncker S, Laurent T, Khanal B, Chappuis F, Dujardin JC (2005) Gene expression analysis of the mechanism of natural Sb(V) resistance in Leishmania donovani isolates from Nepal. Antimicrob Agents Chemother 49:4616-4621
6. Dube A, Singh N, Sundar S, Singh N (2005) Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in in vitro and in vivo experimental models. Parasitol Res 96:216-223
7. Ephros M, Bitnun A, Shaked P, Waldman E, Zilberstein D (1999) Stage-specific activity of pentavalent antimony against leishmania donovani axenic amastigotes. Antimicrob Agents Chemother 43:278-282
8. Evans D (1989) Handbook of isolation, characterization and cryopreservation of Leishmania. UNDP/World Bank/WHO
9. Faraut-Gambarelli F, Piarroux R, Deniau M, Giusiano B, Marty P, Michel G, Faugere B, Dumon H (1997) In vitro and in vivo resistance of Leishmania infantum to meglumine antimoniate: a study of 37 strains collected from patients with visceral leishmaniasis. Antimicrob Agents Chemother 41:827-830
10. Ferreira-Pinto KC, Miranda-Vilela AL, Anacleto C, Fernandes AP, Abdo MC, Petrillo-Peixoto ML, Moreira ES (1996) Leishmania (V.) guyanensis: isolation and characterization of glucantime-resistant cell lines. Can J Microbiol 42:944-949
11. Guerin PJ, Olliaro P, Sundar S, Boelaert M, Croft SL, Desjeux P, Wasunna MK, Bryceson AD (2002) Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect Dis 2:494-501
12. Hadighi R, Mohebali M, Boucher P, Hajjaran H, Khamesipour A, Ouellette M (2006) Unresponsiveness to glucantime treatment in Iranian cutaneous leishmaniasis due to drug-resistant Leishmania tropica parasites. PLoS Med 3:e162
13. Jackson JE, Tally JD, Ellis WY, Mebrahtu YB, Lawyer PG, Were JB, Reed SG, Panisko DM, Limmer BL (1990) Quantitative in vitro drug potency and drug susceptibility evaluation of Leishmania ssp. from patients unresponsive to pentavalent antimony therapy. Am J Trop Med Hyg 43:464-480
14. Lira R, Sundar S, Makharia A, Kenney R, Gam A, Saraiva E, Sacks D (1999) Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani. J Infect Dis 180:564-567
15. Mohebali M, Javadian E, Yaghoobi-Ershadi MR, Akhavan AA, Hajjaran H, Abaei MR (2004) Characterization of Leishmania infection in rodents from endemic areas of the Islamic Republic of Iran. East Mediterr Health J 10:591-599
16. Mohebali M, Edrissian GH, Nadim A, Hajjaran H, Akhoundi B, Hooshmand B, Zarei Z, Arshi A, Mirsamadi N, Naeini KM, Mamishi S, Sanati AA, Moshfe AA, Charehdar S, Fakhar M (2006) Application of direct agglutination test (DAT) for the diagnosis and seroepidemiological studies of visceral leishmaniasis in the Islamic Republic of Iran. Iran J Parasitol 1:15-25
17. Murray HW, Berman J, Davies CR, Saravia NG (2005) Advances in leishmaniasis. Lancet 366:1561-1577
18. Olliaro PL, Guerin PJ, Gerstl S, Haaskjold AA, Rottingen JA, Sundar S (2005) Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004. Lancet Infect Dis 5:763-774
19. Rojas R, Valderrama L, Valderrama M, Varona MX, Ouellette M, Saravia NG (2006) Resistance to antimony and treatment failure in human leishmania (viannia) infection. J Infect Dis 193:1375-1383
20. Roy G, Dumas C, Sereno D, Wu Y, Singh AK, Tremblay MJ, Ouellette M, Olivier M, Papadopoulou B (2000) Episomal and stable expression of the luciferase reporter gene for quantifying Leishmania spp. infections in macrophages and in animal models (in process citation). Mol Biochem Parasitol 110:195-206
21. Seifert K, Croft SL (2006) In vitro and in vivo interactions between miltefosine and other antileishmanial drugs. Antimicrob Agents Chemother 50:73-79
22. Sereno D, Roy G, Lemesre JL, Papadopoulou B, Ouellette M (2001) DNA Transformation of Leishmania infantum axenic amastigotes and their use in drug screening. Antimicrob Agents Chemother 45:1168-1173
23. Sundar S, More DK, Singh MK, Singh VP, Sharma S, Makharia A, Kumar PC, Murray HW (2000) Failure of pentavalent antimony in visceral leishmaniasis in India: report from the Center of the Indian Epidemic. Clin Infect Dis 31:1104-1107
24. Sundar S, Jha TK, Thakur CP, Engel J, Sindermann H, Fischer C, Junge K, Bryceson A, Berman J (2002) Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 347:1739-1746
25. Thakur CP, Narayan S, Ranjan A (2004) Epidemiological, clinical & pharmacological study of antimony-resistant visceral leishmaniasis in Bihar, India. Indian J Med Res 120:166-172
26. Vergnes B, Gourbal B, Girard I, Sundar S, Drummelsmith J, Ouellette M (2007) A proteomics screen implicates HSP83 and a small kinetoplastid calpain-related protein in drug resistance in Leishmania donovani clinical field isolates by modulating drug-induced programmed cell death. Mol Cell Proteomics 6:88-101
27. Yardley V, Ortuno N, Llanos-Cuentas A, Chappuis F, Doncker SD, Ramirez L, Croft S, Arevalo J, Adaui V, Bermudez H, Decuypere S, Dujardin JC (2006) American tegumentary leishmaniasis: is antimonial treatment outcome related to parasite drug susceptibility? J Infect Dis 194:1168-1175